Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the initiation of patient recruitment for Group Two of its ongoing human clinical study of the Ocumetics Lens, an accommodating intraocular lens designed to provide clear vision at all distances without glasses or contact lenses. The company's clinical facility in Mexico City, which successfully performed Group One surgeries in Fall 2025, has begun identifying and recruiting eligible patients, with surgeries targeted for Fall 2026.
Group One of the study focused solely on safety, and the outcomes met and exceeded the company's expectations regarding the safety, performance, and handling of the lens. Patients from that group are now reaching their 12-month follow-up visits, providing longer-term clinical data that will inform the ongoing development. Building on this positive experience, Group Two will evaluate both safety and vision performance, specifically distance and near vision, using the latest-generation Ocumetics Lens implanted with an enhanced delivery system.
Dean Burns, President and CEO of Ocumetics, expressed excitement about the progress, stating, "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter." He also highlighted the significance of the 12-month milestone for Group One patients, which will provide an important body of longer-term clinical data as the company advances the technology.
The Group Two study is a critical step in the clinical validation of the Ocumetics Lens, which is designed to fit within the natural lens compartment of the eye and utilize the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. The company's technology aims to address the limitations of current intraocular lenses, offering a truly differentiated solution for patients seeking improved vision across a broader range of distances.
Ocumetics Technology Corp. is a Canadian research and product development company focused on developing advanced vision correction solutions. The company is currently in the first-in-human early feasibility study phase, and the initiation of Group Two patient recruitment marks a significant advancement in its clinical program. As the study progresses, the outcomes will be crucial in determining the safety and efficacy of the Ocumetics Lens, bringing the company closer to its goal of transforming the field of ophthalmology.
For more information about Ocumetics and its clinical program, visit the company's profile on NewMediaWire.
